AI enabled PsychoGenics combines AI-enabled phenotypic drug discovery with strong preclinical CNS expertise, presenting a compelling offer to biotech firms seeking faster, data-driven candidate selection and reduced attrition in CNS and orphan disorder programs.

Strategic partnerships Recent collaborations with Sunovion and Carnegie Mellon highlight openness to co-development and platform integration, signaling potential for co-funded projects, technology licensing, or joint drug discovery programs.

Expanded platform Launch of the eCube AI-enabled platform expands the company’s capabilities in behavioral pattern analysis, offering scalable screening for CNS targets and differentiating from traditional CRO services—an attractive hook for partners needing advanced translational readouts.

Strong funding SBIR grant funding and a multi-million revenue range indicate financial stability and growth potential, making PsychoGenics a lower-risk partner for early-stage programs and pilot studies.

Niche expertise Extensive portfolio of validated mouse models for Alzheimer’s, Huntington’s, Parkinson’s, autism, and orphan disorders positions PsychoGenics as a specialized partner for clients pursuing translational, mechanism-driven preclinical data to de-risk pipelines.